Drug vials The majority ofoncology drugs (70 percent) will be high-cost orphan drugs–focusedon relatively small group of patients with rare subsets of cancer.(Photo: Shutterstock)

A new report says the FDA will evaluate more than 150 new drugsfor approval in 2020, with 11 drugs representing potentialblockbuster sales of more than $1 billion each.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Core and Group Health
Employer-Paid